Dr Javad Verdi, from Tehran University of Medical Sciences (TUMS), published a research article in June 2020. The paper showed a promising strategy for the treatment of Hepatocellular Carcinoma (HCC), which remains one of the commonly diagnosed cancer.
In order to expand researches in the field of medical sciences, Dr Javad Verdi stays committed to solving complexities. Dr Javad Verdi's research document was published on 15 June 2020. He made discoveries on how to deal with one of the leading cancers, HCC. In addition to that, HCC is the second most common cause of cancer-related deaths. For the treatment of HCC, Sorafenib, commonly known as Sora, and Mesenchymal stem cells (MSCs) have been suggested as the targeted therapy. More about Dr Verdi can be seen at https://fhpd.ca/
Dr Javad Verdi has been associated with Tehran University of Medical Sciences. He has been working in the department of Tissue Engineering and Applied Cell Sciences. Dr Verdi, along with his peers, studied the effects of Sora and MSCs to mitigate Hepatocellular Carcinoma. He observed that one of the major concerns related to Sora administration was side effects and drug resistance. In his study, the effects of combining Sorafenib and MSCs on tumor regression in xenograft HCC models were evaluated.
The study was conducted on eighteen male nude mice, aged between 6 to 8 weeks. These nude mice were selected as a Xenograft Model. The mice were divided into six groups and were given either Sora, MSCs, a combination of both, or were given none of them at all to create a control group. After six weeks of being implanted with the tumor, they were dissected and the tumor-containing tissues were entirely removed. The study revealed that the combination of Sora and MSCs has by far yielded the most favorable results.
In the ever-expanding researches for cancer, MSCs are becoming a topic of interest among scholars. MSCs are investigated against cancer because of their multipotency and their potential to differentiate between various cell lineages. Furthermore, MSCs are also regarded for their chemotactic properties, which allow them to dwell in tumor-infested regions.
The conclusion from the study conducted by Dr Javad Verdi states: “We conclude that although there is no best way for the treatment of HCC, the combination of sorafenib and MSCs has shown a more promising spotlight to achieve more satisfactory results than using sorafenib as a monotherapy. However, more investigations in similar fields would pave the way for an even more extensive clinical trial.” The statement in the study went on to state “Future research should also focus on the signalling pathways and the molecular mechanisms involved in both the development of HCC and the effects of MSCs on the progression of tumor cells.”
It can be seen from the study conducted by Dr Verdi that Sorafenib along with MSCs can prove advantageous to treat HCC. This study provides a solid foundation for further studies. The study further showed that the local injection of MSCs showed better results in inhibiting the proliferation of tumor cells as compared with systemic IV injections.